|
A blinded study comparing the safety and efficacy of a fully human anti-IL8 monoclonal antibody (ABX-IL8) to placebo in patients with chronic bronchitis and COPD Clinical Trials Facts presented on Clinical Trials Search is not designed to be a substitute for certified medical advice, travels to or treatment with a real dr.. We aren't doctors. Always consult your mD on A blinded study comparing the safety and efficacy of a fully human anti-IL8 monoclonal antibody (ABX-IL8) to placebo in patients with chronic bronchitis and COPD conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. A blinded study comparing the safety and efficacy of a fully human anti-IL8 monoclonal antibody (ABX-IL8) to placebo in patients with chronic bronchitis and COPD Clinical research trials and A blinded study comparing the safety and efficacy of a fully human anti-IL8 monoclonal antibody (ABX-IL8) to placebo in patients with chronic bronchitis and COPD medical trials occur in many of places across the U.S.A.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally assess the effectiveness of new does drugs. The role of the studies / undertakings is to figure out certain human healthcare questions. Clinical trials are a popular means for doctors, government agencies, and private sector corporations to locate treatments for all forms of circumstances, including A blinded study comparing the safety and efficacy of a fully human anti-IL8 monoclonal antibody (ABX-IL8) to placebo in patients with chronic bronchitis and COPD. A blinded study comparing the safety and efficacy of a fully human anti-IL8 monoclonal antibody (ABX-IL8) to placebo in patients with chronic bronchitis and COPD Clinical Trials and other clinical trials permit volunteers to get medical treatment options before they are available to the masses. Most times the human subjects acquire treatment for free of charge, and sometimes they are paid for their time. Occasionally there is a cost for a A blinded study comparing the safety and efficacy of a fully human anti-IL8 monoclonal antibody (ABX-IL8) to placebo in patients with chronic bronchitis and COPD clinical trial. Participants oftentimes recieve the finest healthcare available for their A blinded study comparing the safety and efficacy of a fully human anti-IL8 monoclonal antibody (ABX-IL8) to placebo in patients with chronic bronchitis and COPD condition. Dangers are a reality, nonetheless, and might include extra or frequent physician calls, health hazards (potentially life-endangering), and/or the treatment being ineffectual. Trials are federally regulated with strict guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "A" Clinical Trials Conditions > A blinded study comparing the safety and efficacy of a fully human anti-IL8 monoclonal antibody (ABX-IL8) to placebo in patients with chronic bronchitis and COPD  A blinded study comparing the safety and efficacy of a fully human anti-IL8 monoclonal antibody (ABX-IL8) to placebo in patients with chronic bronchitis and COPD
A blinded study comparing the safety and efficacy of a fully human anti-IL8 monoclonal antibody (ABX-IL8) to placebo in patients with chronic bronchitis and COPD
For Condition: Bronchitis, Chronic,Pulmonary Disease, Chronic Obstructive
Status: Completed
Sponsor(s): Abgenix ,
Synopsis: To determine if ABX-IL8 will improve shortness of breath.
Details: Chronic Obstructive Pulmonary Disease (COPD) is defined as a disease state characterized by the presence of airflow obstruction due to chronic bronchitis or emphysema. The airflow obstruction is generally progressive, may be accompanied by airway hyper-reactivity, and may be partially reversible. Inflammation in the lungs is triggered by exposure to inhaled toxic substances that can lead to tissue damage, mucous secretion, airways narrowing and tissue destruction. Interleukin-8 (IL-8) plays a major role in elevating sputum in patients with COPD and may contribute to tissue destruction. Therefore, the highly specific antibody to IL-8 (such as ABX-IL8) may help to reduce mucous production and tissue destruction.
Eligibility:
Study Type: Interventional, Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study
Minimum Age/Maximum Age: 50 Years/
Genders: Both
Protocol Entry Criteria: Inclusion Criteria: - > 50 years old - > 20 pack-year of smoking - Diagnosed with COPD and chronic bronchitis Exclusion Criteria: - Patients with bronchiectasis, cystic fibrosis, tuberculosis, asthma, alpha-1 antitrypsin deficiency, CHF - Require oxygen therapy - Uncontrolled hypertension - HIV or Hepatitis - Recent history of COPD exacerbation - Patients with cancer - Recent history of infection
Total Enrollment: 150
Location and Contact Information:
Abgenix
Fremont, California, 94555
United States
Additional Information:
Study ID Numbers: ABX-0209;
Study Start Date: December 2001
Record last reviewed: July 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00035828
Other Pulmonary Disease, Chronic Obstructive Studies:
1. Short Course Acute Bacterial Exacerbation of Chronic Bronchitis (ABECB) (750 mg)
2. A blinded study comparing the safety and efficacy of a fully human anti-IL8 monoclonal antibody (ABX-IL8) to placebo in patients with chronic bronchitis and COPD
Related Studies:
Other Pulmonary Disease, Chronic Obstructive Clinical Trials
Other California Clinical Trials
Other Fremont Clinical Trials
A blinded study comparing the safety and efficacy of a fully human anti-IL8 monoclonal antibody (ABX-IL8) to placebo in patients with chronic bronchitis and COPD
|
|
|
|
|
|
|
|
